Document is current
Any future updates will be listed below
-
Authors
Joshi, Monika https://orcid.org/0000-0003-4286-8492
Tuanquin, Leonard
Zhu, Junjia
Walter, Vonn
Schell, Todd
Kaag, Matthew
Kilari, Deepak
Liao, Jiangang
Holder, Sheldon L
Emamekhoo, Hamid
Sankin, Alexander
Merrill, Suzzane
Zheng, Hong
Warrick, Joshua
Hauke, Ralph
Gartrel, Benjamin
Stein, Mark
Drabick, Joseph
Degraff, David J
Zakharia, Yousef https://orcid.org/0000-0001-9480-2626
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02891161 at ClinicalTrials.govnct02891161 at ClinicalTrials.govDocuments that mention this clinical trial
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
https://doi.org/10.1136/jitc-2022-006551
T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer
https://doi.org/10.1136/jitc-2025-012050
nct04216290 at ClinicalTrials.govDocuments that mention this clinical trial
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
https://doi.org/10.1136/jitc-2022-006551
T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer
https://doi.org/10.1136/jitc-2025-012050
Documents that mention this clinical trial
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
https://doi.org/10.1136/jitc-2022-006551
-
Funding
Funding for this research was provided by:
AstraZeneca Schweiz (ESR-15-11352)
Pennsylvania State University (NA)
- License Information
